MEI Pharma Net Worth
MEI Pharma Net Worth Breakdown | MEIP |
MEI Pharma Net Worth Analysis
MEI Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including MEI Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of MEI Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform MEI Pharma's net worth analysis. One common approach is to calculate MEI Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares MEI Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing MEI Pharma's net worth. This approach calculates the present value of MEI Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of MEI Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate MEI Pharma's net worth. This involves comparing MEI Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into MEI Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if MEI Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding MEI Pharma's net worth research are outlined below:
| MEI Pharma generated a negative expected return over the last 90 days | |
| MEI Pharma has a very high chance of going through financial distress in the upcoming years | |
| MEI Pharma currently holds about 153.25 M in cash with (50.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15. | |
| Latest headline from thelincolnianonline.com: Short Interest in MEI Pharma, Inc. Decreases By 27.6 |
MEI Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in MEI Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MEI Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 24th of September 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
MEI Pharma Target Price Consensus
MEI target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. MEI Pharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Hold |
Most MEI analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand MEI stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of MEI Pharma, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMEI Pharma Target Price Projection
MEI Pharma's current and average target prices are 2.43 and 20.00, respectively. The current price of MEI Pharma is the price at which MEI Pharma is currently trading. On the other hand, MEI Pharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On MEI Pharma Target Price
Know MEI Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MEI Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MEI Pharma backward and forwards among themselves. MEI Pharma's institutional investor refers to the entity that pools money to purchase MEI Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 23.4 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 22.6 K | |
| State Street Corp | 2024-12-31 | 17.8 K | |
| Ubs Group Ag | 2024-12-31 | 11.2 K | |
| Virtu Financial Llc | 2024-12-31 | 10.7 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 5.8 K | |
| Newbridge Financial Services Group, Inc. | 2024-12-31 | 2 K | |
| Group One Trading, Lp | 2024-12-31 | 2 K | |
| Tower Research Capital Llc | 2025-12-31 | 1.4 K | |
| Anson Funds Management Lp | 2024-12-31 | 1.1 M | |
| Cable Car Capital Llc | 2024-12-31 | 611.4 K |
Follow MEI Pharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.19 M.Market Cap |
|
Project MEI Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.39 | 0.41 | |
| Return On Capital Employed | 0.40 | 0.42 | |
| Return On Assets | 0.39 | 0.41 | |
| Return On Equity | 0.48 | 0.51 |
When accessing MEI Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures MEI Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of MEI Pharma's profitability and make more informed investment decisions.
Evaluate MEI Pharma's management efficiency
MEI Pharma has return on total asset (ROA) of (0.3068) % which means that it has lost $0.3068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9368) %, meaning that it created substantial loss on money invested by shareholders. MEI Pharma's management efficiency ratios could be used to measure how well MEI Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/05/2025, Return On Tangible Assets is likely to grow to 0.41. Also, Return On Capital Employed is likely to grow to 0.42. At this time, MEI Pharma's Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 03/05/2025, Non Current Liabilities Other is likely to grow to about 26.8 M, while Total Current Liabilities is likely to drop slightly above 8.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.70 | 5.41 | |
| Tangible Book Value Per Share | 5.70 | 5.41 | |
| Enterprise Value Over EBITDA | 0.52 | 0.55 | |
| Price Book Value Ratio | 0.66 | 0.63 | |
| Enterprise Value Multiple | 0.52 | 0.55 | |
| Price Fair Value | 0.66 | 0.63 | |
| Enterprise Value | 134.9 M | 141.7 M |
The operational strategies employed by MEI Pharma management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MEI Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on MEI Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MEI Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MEI Pharma Corporate Filings
8K | 31st of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 20th of December 2024 Other Reports | ViewVerify | |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 20th of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
MEI Pharma Earnings Estimation Breakdown
The calculation of MEI Pharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of MEI Pharma is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for MEI Pharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
MEI Pharma Earnings Projection Consensus
Suppose the current estimates of MEI Pharma's value are higher than the current market price of the MEI Pharma stock. In this case, investors may conclude that MEI Pharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and MEI Pharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2025 | Current EPS (TTM) | |
| 1 | 51.72% | -2.76 | 0.0 | -5.73 |
MEI Pharma Earnings per Share Projection vs Actual
Actual Earning per Share of MEI Pharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering MEI Pharma predict the company's earnings will be in the future. The higher the earnings per share of MEI Pharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.MEI Pharma Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as MEI Pharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of MEI Pharma should always be considered in relation to other companies to make a more educated investment decision.MEI Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact MEI Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-09-19 | 2024-06-30 | -1.43 | -2.76 | -1.33 | 93 | ||
2024-05-09 | 2024-03-31 | -1.52 | -1.37 | 0.15 | 9 | ||
2024-02-13 | 2023-12-31 | -1.32 | -1.66 | -0.34 | 25 | ||
2023-11-09 | 2023-09-30 | -2.12 | 8.46 | 10.58 | 499 | ||
2023-09-26 | 2023-06-30 | -2.41 | -1.51 | 0.9 | 37 | ||
2023-05-11 | 2023-03-31 | -2.87 | -2.32 | 0.55 | 19 | ||
2023-02-09 | 2022-12-31 | -0.15 | 0.08 | 0.23 | 153 | ||
2022-11-14 | 2022-09-30 | -0.14 | -0.12 | 0.02 | 14 | ||
2022-09-08 | 2022-06-30 | -0.19 | -0.12 | 0.07 | 36 | ||
2022-05-23 | 2022-03-31 | -0.18 | -0.07 | 0.11 | 61 | ||
2022-02-10 | 2021-12-31 | -0.2 | -0.05 | 0.15 | 75 | ||
2021-11-10 | 2021-09-30 | -0.13 | -0.11 | 0.02 | 15 | ||
2021-09-02 | 2021-06-30 | -0.17 | -0.05 | 0.12 | 70 | ||
2021-05-06 | 2021-03-31 | -0.16 | -0.28 | -0.12 | 75 | ||
2021-02-04 | 2020-12-31 | -0.13 | -0.1 | 0.03 | 23 | ||
2020-11-10 | 2020-09-30 | -0.08 | -0.02 | 0.06 | 75 | ||
2020-09-09 | 2020-06-30 | 0.22 | -0.19 | -0.41 | 186 | ||
2020-05-07 | 2020-03-31 | -0.14 | -0.04 | 0.1 | 71 | ||
2020-02-06 | 2019-12-31 | -0.17 | -0.26 | -0.09 | 52 | ||
2019-11-07 | 2019-09-30 | -0.17 | -0.04 | 0.13 | 76 | ||
2019-08-28 | 2019-06-30 | -0.2 | -0.15 | 0.05 | 25 | ||
2019-05-09 | 2019-03-31 | -0.17 | -0.24 | -0.07 | 41 | ||
2019-02-07 | 2018-12-31 | -0.12 | -0.15 | -0.03 | 25 | ||
2018-11-08 | 2018-09-30 | -0.12 | -0.21 | -0.09 | 75 | ||
2018-08-30 | 2018-06-30 | -0.2 | -0.13 | 0.07 | 35 | ||
2018-05-09 | 2018-03-31 | -0.24 | -0.16 | 0.08 | 33 | ||
2018-02-08 | 2017-12-31 | -0.28 | -0.16 | 0.12 | 42 | ||
2017-11-08 | 2017-09-30 | -0.27 | -0.24 | 0.03 | 11 | ||
2017-09-05 | 2017-06-30 | -0.16 | -0.12 | 0.04 | 25 | ||
2017-05-04 | 2017-03-31 | -0.04 | -0.02 | 0.02 | 50 | ||
2017-02-08 | 2016-12-31 | -0.28 | 0.32 | 0.6 | 214 | ||
2016-11-09 | 2016-09-30 | -0.15 | -0.12 | 0.03 | 20 | ||
2016-09-06 | 2016-06-30 | -0.2 | -0.17 | 0.03 | 15 | ||
2016-05-05 | 2016-03-31 | -0.16 | -0.16 | 0.0 | 0 | ||
2016-02-05 | 2015-12-31 | -0.15 | -0.15 | 0.0 | 0 | ||
2015-11-06 | 2015-09-30 | -0.17 | -0.13 | 0.04 | 23 | ||
2015-09-02 | 2015-06-30 | -0.21 | -0.13 | 0.08 | 38 | ||
2015-05-07 | 2015-03-31 | -0.27 | -0.27 | 0.0 | 0 | ||
2015-02-06 | 2014-12-31 | -0.39 | -0.39 | 0.0 | 0 | ||
2014-11-06 | 2014-09-30 | -0.38 | -0.42 | -0.04 | 10 | ||
2014-09-09 | 2014-06-30 | -0.35 | -0.4 | -0.05 | 14 | ||
2014-05-08 | 2014-03-31 | -0.3 | -0.34 | -0.04 | 13 | ||
2014-02-11 | 2013-12-31 | -0.24 | -0.32 | -0.08 | 33 | ||
2013-11-08 | 2013-09-30 | -0.2 | -0.29 | -0.09 | 45 | ||
2013-09-18 | 2013-06-30 | -0.14 | -0.19 | -0.05 | 35 | ||
2013-05-09 | 2013-03-31 | -0.2 | -0.18 | 0.02 | 10 | ||
2013-02-12 | 2012-12-31 | -0.23 | -0.5 | -0.27 | 117 | ||
2012-11-13 | 2012-09-30 | -0.84 | -0.72 | 0.12 | 14 | ||
2012-09-18 | 2012-06-30 | -0.9 | -0.72 | 0.18 | 20 | ||
2012-05-15 | 2012-03-31 | -0.78 | -0.9 | -0.12 | 15 | ||
2008-09-15 | 2008-06-30 | -2.4 | -3.0 | -0.6 | 25 | ||
2008-05-07 | 2008-03-31 | -3.6 | -3.0 | 0.6 | 16 | ||
2008-02-08 | 2007-12-31 | -3.6 | -1.8 | 1.8 | 50 | ||
2007-11-07 | 2007-09-30 | -1.8 | -3.0 | -1.2 | 66 | ||
2007-09-27 | 2007-06-30 | -1.8 | -1.8 | 0.0 | 0 | ||
2007-05-08 | 2007-03-31 | -4.8 | -1.8 | 3.0 | 62 | ||
2007-02-08 | 2006-12-31 | -1.8 | -1.8 | 0.0 | 0 | ||
2006-11-08 | 2006-09-30 | -1.8 | -7.8 | -6.0 | 333 | ||
2006-09-01 | 2006-06-30 | -3.6 | -0.6 | 3.0 | 83 | ||
2006-05-09 | 2006-03-31 | -3 | -3.6 | -0.6 | 20 | ||
2006-02-10 | 2005-12-31 | -2.4 | -1.8 | 0.6 | 25 | ||
2005-11-14 | 2005-09-30 | -2.4 | -1.8 | 0.6 | 25 | ||
2005-09-14 | 2005-06-30 | -2.4 | -2.4 | 0.0 | 0 | ||
2005-05-13 | 2005-03-31 | -2.4 | -1.8 | 0.6 | 25 | ||
2005-02-11 | 2004-12-31 | -1.2 | -1.2 | 0.0 | 0 | ||
2004-11-15 | 2004-09-30 | -1.8 | -1.2 | 0.6 | 33 | ||
2004-09-10 | 2004-06-30 | -1.8 | -1.2 | 0.6 | 33 | ||
2004-05-14 | 2004-03-31 | -1.2 | -1.8 | -0.6 | 50 |
MEI Pharma Corporate Management
| BA Esq | COO Counsel | Profile | |
| Anne Frese | Chief Officer | Profile | |
| Eugene Park | VP Marketing | Profile | |
| Virginia Sankey | VP Fin | Profile | |
| JD Esq | Chief Officer | Profile | |
| Eric Deng | VP Operations | Profile |
Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.